PS - So it seems that unit sales are actually declining. That is in contrast to an ever more crowded infusion center here. So maybe our neuro is unusually pro-T.
Copaxone Continues Cleaning Tysabri’s Clock in US Market
[Updated for 3Q10 Copaxone sales.]
The US market is the one of consequence for MNTA investors insofar as this is where MNTA/NVS have submitted an ANDA for generic Copaxone. Below are Tysabri and Copaxone US sales for the past nine quarters with the recent year-over-year and quarter-over-quarter growth rates. Copaxone outsells Tysabri in the US by approximately 4:1.